[
  {
    "column": "S6",
    "description": "S6: How many years have you been in clinical practice, post residency/training?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S8r1",
    "description": "S8r1: Treating/Managing patients - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r2",
    "description": "S8r2: Performing academic functions (e.g., teaching, publishing) - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r3",
    "description": "S8r3: Participating in clinical research - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r4",
    "description": "S8r4: Performing other functions - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S10",
    "description": "S10: Using your best estimate, how many adult patients, age 18 or older, do you personally manage in your practice in a month? By ‘personally’, we mean patients for whom you are a primary treatment decision maker.",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S11",
    "description": "S11: Of those adult patients for whom you are the primary treatment decision maker, roughly how many have a confirmed diagnosis of hypercholesterolemia with established cardiovascular disease (CVD)?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S12r1",
    "description": "S12r1: Over 5 years ago - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S12",
    "context": ""
  },
  {
    "column": "S12r2",
    "description": "S12r2: Within the last 3-5 years - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S12",
    "context": ""
  },
  {
    "column": "S12r3",
    "description": "S12r3: Within the last 1-2 years - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S12",
    "context": ""
  },
  {
    "column": "S12r4",
    "description": "S12r4: Within the last year - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S12",
    "context": ""
  },
  {
    "column": "A3r1",
    "description": "A3r1: Statin only (i.e., no additional therapy) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3",
    "context": ""
  },
  {
    "column": "A3r2",
    "description": "A3r2: Leqvio (inclisiran) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3",
    "context": ""
  },
  {
    "column": "A3r3",
    "description": "A3r3: Praluent (alirocumab) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3",
    "context": ""
  },
  {
    "column": "A3r4",
    "description": "A3r4: Repatha (evolocumab) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3",
    "context": ""
  },
  {
    "column": "A3r5",
    "description": "A3r5: Zetia (ezetimibe) or generic ezetimibe - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3",
    "context": ""
  },
  {
    "column": "A3r6",
    "description": "A3r6: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3",
    "context": ""
  },
  {
    "column": "A3r7",
    "description": "A3r7: Other - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3",
    "context": ""
  },
  {
    "column": "A3ar1c1",
    "description": "A3ar1c1: In addition to statin - Leqvio (inclisiran) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar1c2",
    "description": "A3ar1c2: Without a statin - Leqvio (inclisiran) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar2c1",
    "description": "A3ar2c1: In addition to statin - Praluent (alirocumab) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar2c2",
    "description": "A3ar2c2: Without a statin - Praluent (alirocumab) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar3c1",
    "description": "A3ar3c1: In addition to statin - Repatha (evolocumab) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar3c2",
    "description": "A3ar3c2: Without a statin - Repatha (evolocumab) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar4c1",
    "description": "A3ar4c1: In addition to statin - Zetia (ezetimibe) or generic ezetimibe - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar4c2",
    "description": "A3ar4c2: Without a statin - Zetia (ezetimibe) or generic ezetimibe - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar5c1",
    "description": "A3ar5c1: In addition to statin - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3ar5c2",
    "description": "A3ar5c2: Without a statin - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3a",
    "context": ""
  },
  {
    "column": "A3br1c1",
    "description": "A3br1c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Leqvio (inclisiran) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without a",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br1c2",
    "description": "A3br1c2: AFTER trying another lipid-lowering therapy - Leqvio (inclisiran) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without a statin did so",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br2c1",
    "description": "A3br2c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Praluent (alirocumab) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br2c2",
    "description": "A3br2c2: AFTER trying another lipid-lowering therapy - Praluent (alirocumab) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without a statin did s",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br3c1",
    "description": "A3br3c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Repatha (evolocumab) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br3c2",
    "description": "A3br3c2: AFTER trying another lipid-lowering therapy - Repatha (evolocumab) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without a statin did so",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br4c1",
    "description": "A3br4c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Zetia (ezetimibe) or generic ezetimibe - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received tha",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br4c2",
    "description": "A3br4c2: AFTER trying another lipid-lowering therapy - Zetia (ezetimibe) or generic ezetimibe - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy witho",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br5c1",
    "description": "A3br5c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res Pati",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A3br5c2",
    "description": "A3br5c2: AFTER trying another lipid-lowering therapy - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] w",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A3b",
    "context": ""
  },
  {
    "column": "A4r1c1",
    "description": "A4r1c1: Statin only (i.e., no additional therapy) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exer",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r2c1",
    "description": "A4r2c1: Leqvio (inclisiran) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in comb",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r3c1",
    "description": "A4r3c1: Praluent (alirocumab) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in co",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r4c1",
    "description": "A4r4c1: Repatha (evolocumab) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in com",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r5c1",
    "description": "A4r5c1: Zetia (ezetimibe) or generic ezetimibe - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercis",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r6c1",
    "description": "A4r6c1: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r7c1",
    "description": "A4r7c1: Other - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with o",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r1c2",
    "description": "A4r1c2: Statin only (i.e., no additional therapy) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exer",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r2c2",
    "description": "A4r2c2: Leqvio (inclisiran) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in comb",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r3c2",
    "description": "A4r3c2: Praluent (alirocumab) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in co",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r4c2",
    "description": "A4r4c2: Repatha (evolocumab) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in com",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r5c2",
    "description": "A4r5c2: Zetia (ezetimibe) or generic ezetimibe - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercis",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r6c2",
    "description": "A4r6c2: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r7c2",
    "description": "A4r7c2: Other - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with o",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4ar1c1",
    "description": "A4ar1c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Leqvio (inclisiran) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. without",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar1c2",
    "description": "A4ar1c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Leqvio (inclisiran) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. without",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar2c1",
    "description": "A4ar2c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Praluent (alirocumab) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. withou",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar2c2",
    "description": "A4ar2c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Praluent (alirocumab) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. withou",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar3c1",
    "description": "A4ar3c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Repatha (evolocumab) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. without",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar3c2",
    "description": "A4ar3c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Repatha (evolocumab) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. without",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar4c1",
    "description": "A4ar4c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Zetia (ezetimibe) or generic ezetimibe - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar4c2",
    "description": "A4ar4c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Zetia (ezetimibe) or generic ezetimibe - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar5c1",
    "description": "A4ar5c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4ar5c2",
    "description": "A4ar5c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4a",
    "context": ""
  },
  {
    "column": "A4br1c1",
    "description": "A4br1c1: Next treatment allocation - Leqvio (inclisiran) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin woul",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br1c2",
    "description": "A4br1c2: Next treatment allocation - Leqvio (inclisiran) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin woul",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br2c1",
    "description": "A4br2c1: Next treatment allocation - Praluent (alirocumab) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin wo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br2c2",
    "description": "A4br2c2: Next treatment allocation - Praluent (alirocumab) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin wo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br3c1",
    "description": "A4br3c1: Next treatment allocation - Repatha (evolocumab) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin wou",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br3c2",
    "description": "A4br3c2: Next treatment allocation - Repatha (evolocumab) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin wou",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br4c1",
    "description": "A4br4c1: Next treatment allocation - Zetia (ezetimibe) or generic ezetimibe - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy wi",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br4c2",
    "description": "A4br4c2: Next treatment allocation - Zetia (ezetimibe) or generic ezetimibe - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy wi",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br5c1",
    "description": "A4br5c1: Next treatment allocation - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A4br5c2",
    "description": "A4br5c2: Next treatment allocation - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4b",
    "context": ""
  },
  {
    "column": "A6r1",
    "description": "A6r1: Start statin first, add/switch to ezetimibe or Nexletol/Nexlizet if needed - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or i",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r2",
    "description": "A6r2: Start statin and ezetimibe or Nexletol/Nexlizet at the same time - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combinat",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r3",
    "description": "A6r3: Start ezetimibe or Nexletol/Nexlizet, no statin - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other LD",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r4",
    "description": "A6r4: Start statin first, add/switch to PCSK9i if needed - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r5",
    "description": "A6r5: Start statin and PCSK9i at the same time - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other LDL-C-low",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r6",
    "description": "A6r6: Start PCSK9i, no statin - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other LDL-C-lowering therapies,",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r7",
    "description": "A6r7: Start statin first, add/switch to ezetimibe or Nexletol/Nexlizet if needed, add/switch to PCSK9i if needed after that - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r8",
    "description": "A6r8: Other - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other LDL-C-lowering therapies, in adults with pri",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "B1r1",
    "description": "B1r1: Not insured - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B1",
    "context": ""
  },
  {
    "column": "B1r2",
    "description": "B1r2: Private insurance provided by employer / purchased in exchange - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B1",
    "context": ""
  },
  {
    "column": "B1r3",
    "description": "B1r3: Traditional Medicare (Medicare Part B Fee for Service) - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B1",
    "context": ""
  },
  {
    "column": "B1r4",
    "description": "B1r4: Traditional Medicare with supplemental insurance - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B1",
    "context": ""
  },
  {
    "column": "B1r5",
    "description": "B1r5: Private Medicare (Medicare Advantage / Part C managed through Private payer) - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B1",
    "context": ""
  },
  {
    "column": "B1r6",
    "description": "B1r6: Medicaid - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B1",
    "context": ""
  },
  {
    "column": "B1r7",
    "description": "B1r7: Veterans Administration (VA) - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B1",
    "context": ""
  },
  {
    "column": "B1r8",
    "description": "B1r8: Other - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B1",
    "context": ""
  },
  {
    "column": "B4",
    "description": "B4: How many physicians are in your practice?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  }
]